Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 32.24% from the company’s previous close.

Several other analysts also recently issued reports on the stock. Benchmark reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. TheStreet cut Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. The Goldman Sachs Group reduced their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Finally, JMP Securities reiterated a “market outperform” rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $53.29.

Halozyme Therapeutics Stock Down 0.6 %

Shares of NASDAQ:HALO opened at $37.81 on Wednesday. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 52-week low of $29.85 and a 52-week high of $45.00. The company has a 50 day moving average of $39.50 and a two-hundred day moving average of $37.76. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 17.92, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. As a group, analysts forecast that Halozyme Therapeutics will post 3.33 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the sale, the senior vice president now owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 over the last 90 days. Insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently added to or reduced their stakes in HALO. TD Asset Management Inc increased its stake in Halozyme Therapeutics by 517.0% during the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares during the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics during the fourth quarter worth about $44,935,000. Epoch Investment Partners Inc. increased its holdings in shares of Halozyme Therapeutics by 250.5% in the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after acquiring an additional 831,199 shares during the period. Macquarie Group Ltd. increased its holdings in shares of Halozyme Therapeutics by 22.8% in the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock worth $122,226,000 after acquiring an additional 595,220 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Halozyme Therapeutics by 174.5% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after acquiring an additional 563,989 shares during the period. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.